Research is a long-term endeavor requiring patience and foresight. Utah already ranks first in innovation, as previously ...

Gilead's chief executive calls lenacapavir a once in a decade medicine. The HIV treatment could push Gilead stock further up ...

Morgan Stanley has upgraded Gilead Sciences (GILD) to overweight from equal weight, citing the company's HIV drug lenacapavir. Read more here.

Promising new drugs to prevent and treat HIV have the potential to transform the response to the disease. But getting these ...

Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:GILD) to "overweight" from "equal weight," raising its price target to $113 from $87 on HIV prevention drug Lenacapavir (PrEP) and next-gen HIV ...

Technology is advancing at a rapid pace, transforming all areas of our lives and leaving barely any aspect of it unimpacted.  This is not a new phenomenon by any degree. Many centuries ago, the ...

The diagnosed prevalent cases of human immunodeficiency virus (HIV) are projected to increase globally at an annual growth ...

Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence Flynn ...

Addressing stigma, inequity, and access to HIV innovations remains critical to progress in the global HIV response, says IAS ...

ShareThe World Health Organisation (WHO) is assembling a Guideline Development Group (GDG) to craft recommendations for the ...

The moves come as Wall Street is gearing up for December's nonfarm payrolls reading, which is scheduled to come out at 8:30 a ...

A Guideline Development Group (GDG) meeting at the end of the month aims to establish new guidelines for lenacapavir, a twice ...